Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Breaking Up With Breakthrough: Trevena And Tonix Lose Designation, But Continue With Pivotal Plans

Mar 11 2019

• By Bridget Silverman

Related Content

Breakthrough Denial Doesn't Mean US FDA Won't Bring Full Resources To Application

Jan 09 2019

Trevena's IV Opioid Not Quite 'Ready for Primetime,' US FDA Panel Concludes

Oct 12 2018

Breakthrough Designation Rescissions: Who Might US FDA Drop Next?

Mar 11 2019

A Phoenix Turn For Tonix: Rising From Phase III Ashes With New PTSD Approach

Oct 08 2018

Related Companies

Tonix Pharmaceuticals Holding Corp.

Trevena Inc.

Additional Topics

United States Review Pathway Drug Approval Standards Drug Review Regulation Neurology BioPharmaceutical

More from Review Pathways

More from Pathways & Standards

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window